tailieunhanh - báo cáo khoa học: " Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice | Sun et al. Journal of Experimental Clinical Cancer Research 2011 30 30 http content 30 1 30 Journal of Experimental Clinical Cancer Research RESEARCH Open Access Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases implications for clinical practice Leina Sun1 Qiang Zhang2 Huanling Luan1 Zhongli Zhan1 Changli Wang2 Baocun Sun1 3 4 Abstract Background Epidermal growth factor receptor tyrosine kinase inhibitors EGFR-TKI have been widely used for the treatment of non-small cell lung cancer NSCLC . KRAS and EGFR somatic mutations in NSCLC may predict resistance and responsiveness to TKI respectively. Nevertheless most research to date has been conducted on samples from primary tumors. For many patients with advanced disease their samples can only be obtained from metastases for test. The molecular characteristics of metastasized tumors may be different from those of primary tumors. Materials and methods Mutation status of KRAS and EGFR between primary tumors and local lymph node metastases of 80 Chinese patients with NSCLC were analyzed by direct sequencing. Five of them were given gefitinib as neoadjunvant treatment after the EGFR-TKI sensitive mutations were detected in their biopsies of mediastinal lymph nodes metastases. McNemar s test was used to compare the EGFR and KRAS mutation status between primary tumors and corresponding local lymph node metastases. Data evaluation was carried out with statistical software. Results Among the 160 samples one primary tumor and seven metastases were identified with KRAS mutations and 21 primary tumors and 26 metastases were found to have EGFR mutations. KRAS and EGFR mutation status was different between primary tumors and corresponding metastases in 6 and 7 patients respectively. One patient with no TKI sensitive mutations detected in the primary tumor showed disease progression. Conclusion Our results suggest that a considerable .